Cellectar Biosciences Inc. Earnings Preview and Outlook
Cellectar Biosciences Inc., a pharmaceutical company specializing in cancer treatment and diagnosis, is set to release its second-quarter 2025 earnings on August 14, 2025. The company, operating in the Health Care sector with a focus on Biotechnology, is based in Middleton, United States, and trades on the Nasdaq stock exchange.
Earnings Expectations
Analysts have projected a loss of $3.719 per share for the quarter ending June 30, 2025. This represents an improvement from the previous year’s loss of $5.400 per share. The company is expected to report a revenue of $0.0 million for the quarter, consistent with the same period last year.
For the full fiscal year, analysts anticipate an average loss of $15.357 per share, compared to $42.000 per share in the previous year. The projected annual revenue remains at $0.0 million, unchanged from the prior year.
Company Overview
Cellectar Biosciences Inc. is engaged in developing drugs for cancer treatment and diagnosis, serving the medical, pharmaceutical, and healthcare industries. The company’s market capitalization stands at $12,960,000 USD, with a close price of $4.42 as of August 12, 2025. The 52-week high was $68.7 on August 29, 2024, and the 52-week low was $4.36 on June 30, 2025. The price-to-earnings ratio is currently -0.253.
For more information, visit Cellectar Biosciences’ website at www.cellectar.com .
Sources
- Seeking Alpha: Cellectar Biosciences Q2 2025 Earnings Preview
- Benzinga: A Peek at Cellectar Biosciences’ Future Earnings
- Finanzen.net: Ausblick: Cellectar Biosciences informiert über die jüngsten Quartalsergebnisse